---
title: "Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291561922.md"
description: "Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock"
datetime: "2026-07-02T14:21:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291561922.md)
  - [en](https://longbridge.com/en/news/291561922.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291561922.md)
generator: "portal-rs"
---

# Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock


### Related Stocks

- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)

## Related News & Research

- [58,059 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Twin Lakes Capital Management LLC](https://longbridge.com/en/news/297400133.md)
- [Protagonist announces Takeda received U.S. FDA approval for MIMRYLO](https://longbridge.com/en/news/297455451.md)
- [PTGX: FDA approved MIMRYLO for polycythemia vera, offering a novel, effective treatment option](https://longbridge.com/en/news/297480963.md)
- [US FDA approves Takeda, Protagonist's drug for rare blood cancer](https://longbridge.com/en/news/297371857.md)
- [Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera](https://longbridge.com/en/news/297376639.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**